News
Arena begins Phase Ib trial of APD334 to treat autoimmune diseases
US-based Arena Pharmaceuticals has started dosing patients in an investigational Phase Ib clinical trial of APD334, an oral drug candidate that targets the sphingosine...
Press Releases
Chemistry: Provence Technologies acquires Synprosis
Provence Technologies acquires SynprosisThe acquisition strengthens Provence Technologies’ expertise in its core business of therapeutic chemistryProvence Technologies Group, a specialist fine chemistry research group,...
News
AstraZeneca’s Bydureon achieves better glycaemic control than insulin glargine in type 2 diabetes
UK-based AstraZeneca has reported results from its longest, randomised, head-to-head DURATION-3 trial of exenatide once-weekly, a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist used to...
News
KIP THE HUMANS: DRUG DISCOVERY BY SIMULATING CELLS
The future of medicine, we're often told, will be personalized. We'll have gene therapies, wearables to monitor our vital signs—maybe even new kinds of...
News
Boston Therapeutics begins Phase IIb Sugardown trial for type 2 diabetes patients
US-based Boston Therapeutics (BTI) has started a Phase IIb clinical trial SD-002 to evaluate the efficacy and safety of Sugardown in patients with type...
Press Releases
Only one week left before BIOVISION, June 5 and 6 Cite Internationale in Lyon, France
Disruptive Innovation – Health – Funding | Immunotherapies – Healthy AgeingOnly one week left to join us in Lyon to meet the key international...
Industry Reports
Pivotal Therapeutics Announces First Quarter Financial Results
Pivotal Therapeutics Inc. , a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease (CVD) and overall health, announced its operational...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from up to 5 devices at once
Must read